Pharmafile Logo

Patients and data tracking

- PMLiVE

US Supreme Court asked to block Purdue Pharma bankruptcy settlement

The company has been blamed for fuelling the opioid crisis with the promotion of its drug OxyContin

- PMLiVE

GSK’s Jemperli combination receives FDA approval for endometrial cancer

Approximately 60,000 new cases of endometrial cancer are diagnosed every year in the US

- PMLiVE

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, announced a new team of experts will lead its HEOR & Market Access Scientific Office.

OPEN Health

The 5 W’s of Virtual Patient Engagement

Learn the Who, What, When, Where, and Why (+ How) of virtual patient engagement programs...

Impetus Digital

- PMLiVE

FDA approves second over-the-counter naloxone nasal spray for opioid overdose

Over 105,000 fatal opioid overdoses were reported in the US between 2022 and 2023

- PMLiVE

Johnson & Johnson’s attempt to resolve talcum powder lawsuits fails a second time

The company’s subsidiary LTL Management is set to appeal the court’s decision

Can Cinderella save us?

New study finds vaccines could avert 500,000 antimicrobial resistance deaths each year

AMR has been declared by WHO as one of the top ten threats to global public health

Biogen Idec building

Biogen to acquire Reata for approximately $7.3bn

The deal gives Biogen access to a recently launched therapy for Friedreich's ataxia

- PMLiVE

Merck’s Keytruda combination shows promise in late-stage breast cancer study

More than 290,000 people are expected to be diagnosed with breast cancer in the US this year

- PMLiVE

UKHSA data reveals a 45% decline in hepatitis C prevalence in England

More than 80,000 people have been treated for the virus by NHS England since 2015

- PMLiVE

UK experts and politicians meet to discuss challenges faced by progressive MS patients

Primary-progressive MS accounts for approximately 10-15% of multiple sclerosis cases

- PMLiVE

AstraZeneca’s rare disease unit to acquire Pfizer’s early-stage gene therapies for $1bn

The transaction could potentially see staff associated with the portfolio move to Alexion

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links